A Belgian company is looking for a new method / product to transfect plasmid DNA into eukaryotic cells in vivo (in animals / human) without the use of viral vectors or apparatus. The method should work in muscle cells and other tissues. The company is able to perform research & development if the development is not finalized. Different kind of agreements; commercial agreement with technical support, license agreement or research agreement, can be considered depending on the level of developme
The aim of the method / product is to transfect plasmid DNA into cells in vivo and especially in muscle cells without the use of viral vectors and without using a specific apparatus (as an electroporator). The product can be a recombinant protein, chemical product... It should not be toxic since it is planned to use it in vivo (including humans). Production costs should be reduced in order to be competitive compared to the production of viral vectors. The method should be compatible with usual method of injections. If development is not finalized, the company can perform additional tests and R&D (alone or in collaboration). Commercial agreement with technical support, license agreement or research agreement can be considered.
- Type of partner sought: Expertise / knowledge in production of small quantities of the product is sought.
Patent, patent pending or possibility to file a patent to cover the product / method is also sought.
- Specific area of activity of the partner: Academic partner or research organization is sought. The partner could be able to provide first proof of concept and help in the development / industrial production.
02/04/2019 - UK Funding for Innovation
04/06/2019 - Future of Building 2019